Anders Ståhlberg,
Associate Professor, Sahlgrenska Cancer Center,
University of Gothenburg
Anders Ståhlberg is working as principal investigator at the Sahlgrenska Cancer Center, University of Gothenburg in Sweden. He has a PhD in molecular biotechnology and has two post-doc periods working with human embryonic stem cells and tumor biology. Anders primary research interest is to understand molecular mechanisms in tumor initiation, tumor development and stem cell differentiation, focusing on breast cancer and sarcomas. He has developed several strategies for gene expression profiling and rare molecule analysis, especially at the single-cell and single-molecule level. Anders is also leading a Translational Genomics Platform at Sahlgrenska University Hospital, Sweden, which is a research initiative with the attempt to bring liquid biopsy analysis into healthcare.
Considerations and Quality Controls When Analyzing Cell-Free Tumor DNA
Wednesday, 30 October 2019 at 14:30
Add to Calendar ▼2019-10-30 14:30:002019-10-30 15:30:00Europe/LondonConsiderations and Quality Controls When Analyzing Cell-Free Tumor DNACirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA. We have developed an ultrasensitive sequencing technology, SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input. Here, we discuss important considerations for ctDNA detection in plasma, including all experimental steps from sampling to data interpretation. We will also discuss how the use of high fidelity enzymes reduce error rates in barcoded NGS. The use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine.
Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-30 14:30:002019-10-30 15:30:00Europe/LondonConsiderations and Quality Controls When Analyzing Cell-Free Tumor DNACirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
